Dec 21 (Reuters) - Australian Clinical Labs Ltd (ACL) :
- SEES PRO FORMA 1H FY22 TOTAL REVENUE OF BETWEEN A$497.3 MILLION AND A$517.2 MILLION
- SEES PRO FORMA 1H FY22 NPAT OF BETWEEN A$116.3 MILLION AND A$128.0 MILLION
- ANTICIPATE HEIGHTENED VOLUMES OF COVID-19 TESTING TO CONTINUE DURING REMAINDER OF FY22
Dec 21 (Reuters) - Australian Clinical Labs Ltd (ACL) : SEES...
Add to My Watchlist
What is My Watchlist?